Vigabatrin Serum Concentration to Dosage Ratio
No Increase in Carbamazepine-10,11-Epoxide During Addition of Lamotrigine Treatment in Children
Patterns of Azathioprine Metabolites in Neutrophils, Lymphocytes, Reticulocytes, and Erythrocytes
Digoxin Intoxication in a Patient With End-Stage Renal Disease
Lack of Kinetic Interaction Between Valproic Acid Citrus Pectin
Caffeine in Saliva After Peroral Intake
Plasma Itraconazole Concentrations in Patients With Neutropenia
Correlation of Morphine Sulfate in Blood Plasma and Saliva in Pediatric Patients
Elevation of Plasma Carbamazepine Concentrations by Ketoconazole in Patients With Epilepsy
Quantification of the O- and N-Demethylated and the Glucuronidated Metabolites of Codeine Relative to the Debrisoquine Metabolic Ratio in Urine in Ultrarapid, Rapid, and Poor Debrisoquine Hydroxylators
Quick Onset of Severe Abdominal Pain After Codeine in an Ultrarapid Metabolizer of Debrisoquine
Measurement of Low Serum Methotrexate Concentrations With the Syva Emit Methotrexate Assay
1 INTEGRATION OF POPULATION KINETIC SOFTWARE IN CLINICAL PRACTICE
2 IMPACT OF GOAL-ORIENTED MODEL-BASED TDM OF AMINOGLYCOSIDES ON CLINICAL OUTCOME
3 PKBASE - A DATABASE DEVELOPED FOR POPULATION PHARMACOKINETIC STUDIES - CONCEPT AND APPLICATION
4 TOXIC SIDE-EFFECTS OF SOME COMMONLY PRESCRIBED DRUGS
5 VALIDATION OF A STABLE LIQUID SERUM THERAPEUTIC DRUG MONITORING CONTROL
6 ROCHE COBAS INTEGRA DRUG ASSAYS PERFORMANCE EVALUATION
7 THERAPEUTIC DRUG MONITORING GUIDELINES FOR ANTIBIOTICS-A TEAM APPROACH
8 EVALUATION OF TDM ASSAYS ON THE ROCHE COBAS INTEGRA® IN A LARGE REFERENCE LABORATORY
9 QUALITY ASSURANCE STRATEGIES IN DIGOXIN MONITORING. EFFECTIVENESS OF AN EDUCATIONAL INTERVENTION STUDY
10 UKNEQAS AUDIT OF TDM SERVICES
11 SOURCES OF VARIATION IN TDM ASSAYS
12 Acetaminophen and Carbamazepine Monitoring by the Dimension® Clinical Chemistry System
13 APPLICATION OF THE EMIT® 2000 AND EMIT® TDM ASSAYS TO THE OLYMPUS AU600 CHEMISTRY SYSTEM
14 DIRECT EVALUATION OF DOXORUBICIN ACCUMULATION AND EFFLUX IN LIVING BREAST CANCER CELLS EXPRESSING DIFFERENT MECHANISMS OF MULTIDRUG RESISTANCE
15 RIBOZYME-MEDIATED INHIBITION OF HUMAN TELOMERASE ACTIVITIES PRESENT IN CYTOSOL OF DIFFERENT CANCER CELLS
17 CEREBROSPINAL FLUID CONCENTRATION OF ANTICANCER DRUGS ADMINISTERED VIA INTRACRANIAL OR INTRASPINAL ROUTE
18 THE EFFECT OF EGb 761 ON THE DOXORUBICIN CARDIOMYOPATHY
19 INSIGHT INTO THE MECHANISM OF INCREASED BIOAVAILABILITY OF NEORAL® OVER SANDIMMUNE®
20 CLINICAL EXPERIENCE OF MYCOPHENOLIC ACID (MPA) MONITORING FOLLOWING LIVER (LTX) AND KIDNEY TRANSPLANTATION (KTX)
21 REDUCED INCIDENCE OF REJECTION EPISODES IN RENAL ALLOGRAFT RECIPIENTS WHEN AZATHIOPRINE IS MONITORED BY 6-THIOGUANINE NUCLEOTIDES MEASUREMENTS
22 CYCLOSPORIN DOSAGE ESTIMATION BEFORE LUNG TRANSPLANTATION BY AREA-UNDER-THE-CURVE CALCULATIONS IS NOT DEFINITELY REQUIRED
23 DIFFERENCES IN PORTAL AND SYSTEMIC BLOOD PHARMACOKINTICS AFTER ORAL DOSING OF IMMUNOSUPPRESSANTS
24 HPLC(ESI)-MS IDENTIFICATION OF SIROLIMUS (RAPAMYCIN) METABOLITES GENERATED IN A RABBIT MICROSOMAL SYSTEM AND CONFIRMATION WITH HUMAN BLOOD SPECIMENS
25 LONG-TERM EFFECTS OF ANTI-THYMOCYTE GLOBULINS ON LYMPHOCYTE SUBSETS
26 CYCLOSPORIN FRACTION UNBOUND, LIPOPROTEINS AND CLINICAL OUTCOMES AFTER TRANSPLANT
27 THE PHARMACOKINETICS OF A NEW MICROEMULSION OF CYCLOSPORINE A (CyA) IN PEDIATRIC KIDNEY TRANSPLANT PATIENTS
28 NONCOMPARTMENTAL PHARMACOKINETIC ANALYSIS OF MYCOPHENOLIC ACID CONCENTRATIONS IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS
29 PENTAMER FORMATION ASSAY FOR DETERMINATION OF TACROLIMUS AND ITS ACTIVE METABOLITES IN WHOLE BLOOD
30 NEUROTOXIC EFFECTS OF IMMUNOSUPPRESSANTS INVESTIGATED BY MULTINUCLEAR MRS IN VITRO
31 PREDICTING PATIENTS' EXPOSURE TO CYCLOSPORIN FOLLOWING NEORAL®
32 PREDICTION OF MYCOPHENOLIC ACID PLASMA AUC BY A THREE POINT MODEL IN PEDIATRIC KIDNEY RECIPIENTS
33 SALIVARY COMPOSITION IN PATIENTS ON CYCLOSPORINE.
34 TACROLIMUS EXTERNAL QUALITY ASSESSMENT, THE EUROPEAN EXPERIENCE
35 INTRA-INDIVIDUAL VARIABILITY OF CYCLOSPORINE EXPOSURE
36 CYCLOSPORINE (CSA) NEORAL KINETICS STUDIES IN ADULT RENAL TRANSPLANTATION TREATED WITH DILTIAZEM
37 LOCALISED CYCLOSPORIN CONCENTRATIONS IN CARDIAC ALLOGRAFTS
38 INFLUENCE OF POSTTRANSPLANT TIME ON DOSE AND CONCENTRATION OF TACROLIMUS IN LIVER TRANSPLANT PATIENTS
39 ANALYSIS OF THE EFFECTS OF POTENTIAL INTERFERING SUBSTANCES AND CROSS-REACTIVE METABOLITES IN THE PRO-TRAC™ II ELISA FOR THE DETERMINATION OF TACROLIMUS IN WHOLE BLOOD
40 A NOVEL AUTOMATED WHOLE BLOOD SAMPLE PREPARATION SYSTEM FOR USE WITH THE BEHRING EMIT® CYCLOSPORIN METHOD
41 VALIDATION OF BEHRING DIAGNOSTICS EMIT® TO MEASURE MYCOPHENOLIC ACID IN HUMAN PLASMA
42 AUTOMATED HIGH-TURNOVER ANALYSIS OF THE NEW MACROLIDE IMMUNOSUPPRESSANT SDZ RAD IN BLOOD
43 SIMULTANEOUS AND AUTOMATED ANALYSIS OF SIROLIMUS AND CICLOSPORIN IN BLOOD
44 AN EVALUATION OF THE IMx® II TACROLIMUS ASSAY IN ADULT LIVER TRANSPLANT PATIENTS.
45 THE 37 kDa IMMUNOPHILIN HAS URACIL DNA GLYCOSYLASE BUT NOT ROTAMASE ACTIVITY
46 THE RADIORECEPTOR ASSAY FOR SIROLIMUS IN PATIENTS WITH TOXICITY
47 PERFORMANCE CHARACTERISTICS OF THE ABBOTT TACROLIMUS-II IMX ASSAY.
48 CYCLOSPORINE METABOLITE INTERFERENCE IN DIFFERENT CYCLOSPORINE ASSAYS
49 THERAPEUTIC MONITORING OF CYCLOSPORINE-A IN BONE MARROW TRANSPLANTATION - PAST AND PRESENT
50 ANALYTICAL CHARACTERIZATION OF THE PRO-TRAC™ II ELISA FOR THE DETERMINATION OF TACROLIMUS IN WHOLE BLOOD
51 A RAPID HPLC-UV METHOD FOR THE ANALYSIS OF MYCOPHENOLIC ACID IN PLASMA
52 DIURNAL VARIATIONS OF CYCLOSPORINE. COMPARISON BETWEEN CONVENTIONAL AND NEW FORMULATIONS
53 BLOOD EOSINOPHILS, ORAL STEROID DOSAGE AND ACUTE HEART ALLOGRAFT REJECTION
54 A COMPARISON OF THE FIRST AND SECOND GENERATION ABBOTT IMx TACROLIMUS METHODS
55 MYCOPHENOLATE MOFETIL HAS NO EFFECT ON TACROLIMUS PHARMACOKINETICS IN LIVER TRANSPLANT PATIENTS
56 HEPATIC CLEARANCE OF MYCOPHENOLIC ACID IN RATS THE IMPORTANCE OF BINDING TO PLASMA PROTEINS
57 COMPARISON OF THREE DIFFERENT ASSAY METHODS FOR MEASURING TACROLIMUS WHOLE BLOOD CONCENTRATIONS
58 IDENTIFICATION AND CHARACTERIZATION OF TACROLIMUS METABOLITES FROM A RABBIT MICROSOMAL SYSTEM BY LCMS
59 COMPARISON OF TACROLIMUS TROUGH BLOOD CONCENTRATIONS FROM LIVER AND KIDNEY TRANSPLANT RECIPIENTS IN THE EARLY POST-TRANSPLANT PERIOD AS MEASURED BY LCMS, MEIA, AND ELISA
60 MYCOPHENOLIC ACID MEASUREMENT IN PLASMA
61 CLINICAL UTILITY OF THE IMx® TACROLIMUS II (FK506) ASSAY
62 VALIDATION OF A HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR SIROLIMUS
63 TACROLIMUS II MICROPARTICAL ENZYME IMMUNOASSAY BY IMX®
64 EVALUATION OF THE EMIT® MYCOPHENOLIC ACID ASSAY ON THE COBAS MIRA®
65 EVALUATION AND PROTOCOL DEVELOPMENT OF A NEW PRETREATMENT REAGENT FOR THE EMIT® CYCLOSPORINE ASSAY ON THE BOEHRINGER MANNHEIM HITACHI 911® ANALYZER
66 A CYCLOSPORINE IMMUNOASSAY FOR THE AxSYM SYSTEM THAT CORRELATES WITH HPLC
67 TACROLIMUS LEVELS AND DOSES IN PEDIATRIC LIVER TRANSPLANTATION ON RESCUE THERAPY
68 AN HPLC METHOD COMPARED TO THE EMIT® MYCOPHENOLIC ACID ASSAY
69 POPULATION PHARMACOKINETICS OF ORAL CYCLOSPORINE AFTER CARDIAC TRANSPLANTATION
70 EVALUATION OF THE NEW TACROLIMUS II MICROPARTILCE ENZYME IMMUNOASSAY
71 CEDIA® CYCLOSPORINE ASSAY FOR WHOLE BLOOD TESTING
72 QUANTITATION OF SIROLIMUS IN WHOLE BLOOD BY LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY
73 AN HPLC PROCEDURE FOR SIMULTANEOUS DETERMINATION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE IN HUMAN PLASMA
74 THE ACCURACY OF MEASURING CYCLOSPORIN IN CAPILLARY BLOOD SAMPLES
75 A SIMPLE HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF MYCOPHENOLIC ACID AND MYCOPHENOLIC ACID GLUCURONIDE IN PLASMA
76 MYCOPHENOLIC ACID DETERMINATION AFTER SOLID ORGAN TRANSPLANTATION
77 ANTIEPILEPTIC DRUG MONITORING IN PATENTS WITH EPILEPSY BY MICRODIALYSIS
78 ARE PLASMA/HAIR CONCENTRATION RATIOS A USEFUL INDEX OF THERAPEUTIC COMPLIANCE?
79 Optimization of Antiepileptic Drug Therapy Through Measurement of Plasma Level of Antiepileptic Drugs (AEDS)
80 CARBAMAZEPINE EPOXIDE IN TDM
81 MARKED CHANGES IN SERUM ALBUMIN LEVEL AND UNBOUND FRACTION OF VALPROATE IN PATIENTS WITH INFECTIONS
82 VALPROIC ACID ELIMINATION RATE AND URINARY EXCRETION OF ITS GLUCURONIDE CONJUGATE IN PATIENTS WITH EPILEPSY
83 QUANTITATION OF ANTIEPILEPTIC DRUGS WITH HPLC AND TWO FPIA METHODS
84 LAMOTRIGIN DRUG INTERACTIONS IN A TDM MATERIAL
85 INVESTIGATION OF BIAS IN AN EXTERNAL QUALITY ASSESSMENT SCHEME FOR PHENOBARBITAL
86 LAMOTRIGINE & THERAPEUTIC DRUG MONITORING
87 APPLICATION OF THE DRI AED ASSAYS
88 Interference of oxaprozin and 5-(p-hydroxyphenyl)-5-phenylhydantoin in phenytoin immunoassays
89 EVALUATION OF BAYESIAN PREDICTION OF CARBAMAZEPINE IN A PORTUGUESE OUTPATIENT POPULATION
90 A RETROSPECTIVE STUDY OF GENTAMICIN USE BASED ON THERAPEUTIC DRUG MONITORING DATA
91 NEW ANTICONVULSANT TDM - GABAPENTIN
92 DEVELOPMENT OF GENTAMICIN POPULATION PARAMETERS IN PEDIATRIC PATIENTS
93 COMPARATIVE EVALUATION OF A 1- AND 2-COMPARTMENT MODEL FOR I.V. TOBRAMYCIN IN ADULT PATIENTS WITH CYSTIC FIBROSIS
94 Degradation of Vancomycin to CDP-1 as Measured by the COBAS® INTEGRA
95 DEVELOPMENT OF A QUANTITATIVE VANCOMYCIN IMMUNOASSAY FOR THE ABBOTT AxSYM ANALYZER
96 PHARMACOKINETICS OF VANCOMYCIN IN NEONATES
97 NON-PARAMETRIC POPULATION PHARMACOKINETIC ANALYSIS OF ISEPAMICIN (ISP)
98 SERUM FUSIDIC ACID AND CLINDAMYCIN CONCENTRATIONS IN PATIENTS TREATED FOR MRSA INFECTIONS
99 PERFORMANCE OF THE VANCOMYCIN METHOD ON THE DIMENSION® CLINICAL CHEMISTRY SYSTEMS
100 A COMPARATIVE STUDY BETWEEN ONECE (OD) VERSUS TWICE (TD) DAILY ADMINISTRATION OF AMIKACIN IN PEDIATRIC PATIENTS WITH BRONCHOPNEUMONIA
101 EVALUATION OF STANDARD DOSAGE REGIMENS FOR AMIKACIN, GENTAMICIN, NETILMICIN AND VANCOMYCIN
102 TEICOPLANIN PHARMACOKINETICS IN PATIENS UNDERGOING BONE MARROW TRANSPLANTATION. DOSAGE MAINTENANCE REGIME TO ASSURE SERUM THROUGH VALUES ABOVE 10 mg/l
103 SERUM GENTAMICIN LEVELS IN ONCE AND TWICE DAILY REGIMEN IN NEONATES
104 VANCOMYCIN PHARMACOKINETIC PARAMETERS ESTIMATED WITH THREE SAMPLING METHODS
105 DIGOXIN-LIKE IMMUNOREACTIVE FACTOR (DLIF)
106 ROUTINE DIGOXIN RADIOIMMUNOASSAY AS AN INDIRECT METHOD TO MEASURE DIGOXIN-SPECIFIC FAB ANTIBODY FRAGMENTS
107 Interference of digitoxin-like immunoreactive factors in digitoxin immunoassays
108 STABILITY DIGOXIN AND DIGITOXIN IN SPECIMENS COLLECTED IN VACUTAINER BLOOD COLLECTION TUBE
109 DIGOXIN SERUM LEVEL DETERMINATION
110 INTERFERENCE OF UZARA® (AN ANTIDIARRHEAL MEDICATION) IN DIGOXIN IMMUNOASSAYS
111 KINETIC OF DIGOXIN REMOVAL FROM HUMAN MYOCARDIAL TISSUE BY IMMUNE Fab
112 Boehringer Mannheim CEDIA® Procainamide and N-Acetyl Procainamide Assays
113 EVALUATION OF THE DIGOXIN ASSAY FOR THE IMMULITE® CHEMILUMINESCENT IMMUNOASSAY SYSTEM
114 FALSE POSITIVE DIGOXIN LEVELS IN SERA FROM LIVER-TRANSPLANTED PATIENTS
115 PERFORMANCE OF CEDIA® DIGOXIN II ASSAY
116 BOEHRINGER MANNHEIM ELECSYS® DIGOXIN ASSAY
117 INVESTIGATION OF ACS
118 EVALUATION OF THE NEW ACS DIGITOXIN IMMUNOASSAY
119 QUANTITATION OF DIGOXIN IN SERUM BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY
120 Effects of thioridazine on the steady-state plasma concentrations of the enantiomers of mianserin and desmethylmianserin
121 CHIRAL SELECTIVITY OF MACROCYCLIC ANTIBIOTICS - VANCOMYCIN AND TEICOPLANIN COLUMNS FOR THE ANALYSIS OF FLUOXETINE AND NORFLUOXETINE
122 LITHIUM HAND TREMOR
123 COMPARISON OF HPLC AND FPIA FOR THERAPEUTIC DRUG MONITORING OF TRICYCLIC ANTIDEPRESSANTS
124 ANALYSIS OF FLUOXETINE AND NORFLUOXETINE WITHOUT EXTRACTION IN HUMAN SERUM BY HPLC WITH PRECOLUMN FLUORESCENCE DERIVATIZATION
125 CHIRAL HPLC ANALYSIS OF FLUOXETINE AND NORFLUOXETINE WITH ACETYLATED beta- CYCLODEXTRIN COLUMN AND SOLID PHASE EXTRACTION
126 THERAPEUTIC MONITORING OF CLOZAPINE
127 TDM OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS TREATING DEPRESSION IN THE ELDERLY REDUCES DRUG DOSES AND COSTS
128 EVALUATION OF THE BIO-RAD URINE BENZODIAZEPINES BY REMEDi HS
130 SERUM RESPERIDONE AND 9-HYDROXY-RISPERIDONE IN ASIAN SCHIZOPHRENICS
131 HPLC MONITORING OF OLANZAPINE
132 Pharmacokinetics of acetazolamide in patients with uremia
133 L-DOPA THERAPEUTIC MONITORING
134 DIFFERENTIATION OF CLOSELY RELATED DRUGS USING THE REMEDi HS *TM
135 EFFECT OF OZONE ON THE EXPRESSION OF CELL ADHESION MOLECULES ON PERIPHERAL NEUTROPHILS AND ALVEOLAR MACROPHAGES
136 THE ANION GAP AND PROTEIN BINDING
137 TRACING ANILINE EXPOSURE BY MEASURING URINARY p-AMINOPHENOL ON A COBAS MIRA®
138 STAT ALCOHOL AND ETHYLENE GLYCOL TESTING-PROGRESSIVE TESTING IN CLINICAL PRACTICE
139 BENZODIAZEPINE ASSAY FOR THE COBAS® INTEGRA
140 EFFECTS OF POTASSIUM ANTIMONY TARTRATE ON RAT ERYTHROCYTE PHOSPHOFRUCTOKINASE
141 SULPHONYLUREA SERUM DRUG SCREEN
142 CLINICAL APPLICATION OF THE CEDIA METHADONE METABOLITE ASSAY
143 TOXICOLOGY PANEL FOR ETHANOL, SALICYLATE, and ACETAMINOPHEN
144 DETECTION OF PSYCHOACTIVE DRUGS IN HUMAN HAIR BY CAPILLARY ELECTROPHORESIS
145 Toxicology
146 RAT LIVER MICROSOMES - AN EFFICIENT TOOL FOR DEVELOPING GC-MS PROCEDURES FOR DETECTION OF NEW DRUGS OR POISONS IN URINE
147 CONCENTRATIONS OF COCAINE AND METABOLITES IN A DRUG ABUSING POPULATION
148 DETECTION OF BENZODIAZEPINES IN SERUM OR PLASMA ON THE COBAS® INTEGRA.
149 FOODSTUFF CONTAINING HEMP AND THEIR FORENSIC SIGNIFICANCE
150 ANALYSIS OF BARBITURATES IN SERUM OR PLASMA ON THE COBAS® INTEGRA
151 Drugs of Abuse
152 PHARMACOKINETICS OF ECSTASY (MDMA) IN HEALTHY SUBJECTS
153 CONFIRMATIVE TOXICOLOGICAL DRUG ANALYSIS USING HPLC WITH DIODE ARRAY DETECTION
154 IN VITRO, IN HEP G2 CELLS METHOTREXATE-INDUCED TOXICITY IS ENHANCED BY CYTOCHORME P450 2E1 INDUCERS AND PROTECTED BY INHIBITORS OF 2E1
155 DRUGS OF ABUSE TESTING ON A COBAS® INTEGRA
156 URINE LSD SCREENING ON A CONSOLIDATED ANALYZER
157 COMPARISON OF NICCHECK I TEST STRIP WITH IMMUNOASSAY RESULTS ON URINE SPECIMENS FROM PREGNANT SMOKERS
158 EFFECT OF ADULTERANTS ON URINE DRUGS TESTS
159 PROFICIENCY TESTING OF TECHNIQUES FOR DETECTION OF DRUGS OF ABUSE IN URINE
160 IDENTIFICATION OF UNREPORTED COCAINE METABOLITES AND IMPURITIES IN HUMAN URINE BY GC/MS
161 IMMUNOAFFINITY PURIFICATION AND GC/MS CONFIRMATION OF LSD IN URINE AND DETECTION OF A POSSIBLE LSD METABOLITE
162 APPLICATION OF THE EMIT® II AND EMIT® DRUGS-OF-ABUSE ASSAYS TO THE OLYMPUS AU600 CHEMISTRY SYSTEM
163 IMPROVED CEDIA® PCP ASSAY FOR URINE DRUG TESTING
164 A SEMI-AUTOMATED SENSITIVE HPLC METHOD FOR DETERMINATION OF M-CHLOROPHENYLPIPERAZINE IN PLASMA
165 DETECTION OF LAXATIVE ABUSE BY ANALYSIS
166 URINE FINGERPRINTING - DETECTION OF A RESUBMITTED URINE SAMPLE IN AN OPIATE DEPENDENCY PROGRAM
167 VISUALINE II TESTS FOR POINT-OF-CARE DAU
168 SWEAT PATCH VERSUS URINALYSIS IN A DRUG ABUSE CLINIC
169 TLC OF TRAMADOL IN URINE
170 COMPARISON OF A RECEPTOR ASSAY WITH A TRIAGE IMMUNOASSAY FOR URINE BENZODIAZEPINES
171 A BARBITURATE SCREENING IMMUNOASSAY FOR THE ABBOTT AXSYM ANALYZER
172 EVALUATION OF A CDT ASSAY ON BOEHRINGER MANNHEIM/HITACHI ANALYZERS
173 IMPROVED SCREENING FOR AMPHETAMINES IN URINE USING THE CEDIA DAU ASSAY
174 ETHYLMORPHINE URINE PHARMACOKINETICS
175 MONITORING OF METHADONE DOSE INTAKE
176 EVALUATION OF THE CEDIA DAU HIGH SENSITIVITY BENZODIAZEPINE ASSAY
177 OXAPROZIN CROSS-REACTIVITY IN THE BEHRING EMIT dau URINE BENZODIAZEPINE ASSAY
178 OXAPROZIN CROSS-REACTIVITY IN THE BMC CEDIA® DAU URINE BENZODIAZEPINE ASSAY
179 PREVALENCE OF ILLICIT DRUG USE IN THE PROVINCE OF NOVA SCOTIA, CANADA
180 IMPROVED CROSS-REACTIVITY TO α OH TRIAZOLAM IN THE BMC CEDIA® DAU URINE BENZODIAZEPINE ASSAY
181 DETECTION OF KETOBEMIDONE BY GC-MS AFTER AUTOMATED SOLID PHASE EXTRACTION
182 IDENTIFICATION OF FLUNITRAZEPAM METABOLITES IN HUMAN URINE BY ON-LINE COUPLING OF CE WITH ESI-MS
183 PERFORMANCE CHARACTERISTIC OF A NEW LIQUID STABILIZED URINE DRUG OF ABUSE CONTROL (DOA-XSE™) FOR SYVA EMIT ASSAYS
184 RELATIONSHIPS OF CYTOCHROME P450 2C19 GENOTYPES WITH PHARMACOKINETICS AND ANTI-H. PYLORI EFFICACY OF PROTON PUMP INHIBITORS
185 PARTIAL SEQUENCE OF A PIG GENE WITH HIGH HOMOLOGY TO HUMAN CYP3A4
186 HPLC ANALYSIS OF DEXTROMETHORPHAN AND DEXTRORPHAN IN A SINGLE RUN FOR THE DETERMINATION OF METABOLIC PHENOTYPE
187 POLYMORPHIC OXIDATIVE METABOLISM OF PROGUANIL IN A NIGERIAN POPULATION
188 PHARMACOGENETICS
189 RELATIONSHIP BETWEEN ACETYLATION POLYMORPHISM AND RISK OF ATOPIC DISEASES IN CHILDREN
190 POLYMORPHIC N-ACETYLTRANSFERASE 2 IS INHIBITED BY ACETAMINOPHEN IN VITRO & IN VIVO
191 THE RELIABILITY OF URINARY CAFFEINE METABOLIC RATIOS FOR NAT2 PHENOTYPING
192 GENETIC SUSCEPTIBILITY TO VINYL CHLORIDE-ASSOCIATED ANGIOSARCOMA
193 FREE MYCOPHENOLIC ACID PHARMACOKINETICS (PK) IN RENAL TRANSPLANT PATIENTS EARLY AFTER SURGERY
194 SINGLE- AND MULTIPLE-DOSE PHARMACOKINETICS (PK) OF TWO LEFLUNOMIDE ANALOGUES, THE MALONONITRILAMIDES (MNAS) HMR1279 AND HMR1715
195 MOLECULAR MECHANISM OF THE IMMUNOSUPPRESSIVE EFFECT OF LEFLUNOMIDE IN VIVO
196 RELEVANCE OF COMBINED PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) STUDIES TO OPTIMIZE ADMINISTRATION AND EFFICACY OF TWO LEFLUNOMIDE ANALOGUES, THE MALONONITRILAMIDES (MNAS) HMR1279 AND HMR1715.
197 POPULATION PHARMACOKINETICS OF CISAPRIDE IN YOUNG INFANTS WITH GASTRO-ESOPHAGEAL REFLUX
198 PHARMACOKINETICS AND PHARMACODYNAMICS OF THIOPENTONE IN INTENSIVE CARE PATIENTS
199 PHARMACODYNAMIC, PHARMACOKINETIC AND PLASMA MONITORING OF BUSULFAN IN PEDIATRIC PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION.
200 PHARMACOKINETIC ANALYSIS ON STEADY STATE OF GENTAMICIN IN PEDIATRIC CANCER PATIENTS. THRICE AND SINGLE DAILY DOSAGE.
201 PHARMACO-KINETICS AND -DYNAMICS OF NEORAL AND SANDIMMUN AFTER LUNG TRANSPLANTATION
202 INTERACTION BETWEEN TRIAZOLAM AND DILTIAZEM
203 PHARMACOKINETIC ANALYSIS ON STEADY STATE CONDITIONS OF VANCOMYCIN IN PEDIATRIC CANCER PATIENTS.
204 GENTAMICIN PHARMACOKINETIC ANALYSIS ON STEADY-STATE CONDITIONS IN ADULTS SUFFERING FROM HEMATOLOGICAL MALIGNANCIES -ONCE DAILY DOSAGE PROTOCOL
205 STEREOSELECTIVE PHARMACOKINETICS OF ORAL AND INTRAVENOUS ISRADIPINE IN HEALTHY VOLUNTEERS
206 PHARMACOKINETICS/PHARMACODYNEMICS STUDY OF CLONEZEPAM IN CHILDREN WITH EPILEPSY
207 CYCLOSPORINE KINETICS IN UREMIA IN RATS
208 POPULATION PHARMACOKINETICS OF GENTAMICIN IN ONCOLOGY PATIENTS
209 LETHALITY
210 PHARMACOKINETIC STUDIES OF HUMAN RECOMBINANT INTERLEUKIN-2
211 AMIFOSTINE (AMI) PHARMACOKINETICS (PK) IN CANCER PATIENTS
212 DETERMINATION OF ATRACURIUM KINETIC IN PLASMA AND CEREBROSPINAL FLUID BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH FLUORESCENCE DETECTION
213 A Study of the Bioavailability of 99mTc-Rosanol.
214 INFLUENCE OF NUTRITIONAL STATUS ON ACETYL SALICYLIC ACID PHARMACOKINETICS AND ITS METABOLITES IN CHILDREN WITH AUTOIMMUNE DISEASE
215 CLINICAL FARMACOKINETICS OF ORTHOPHEN BY CHILDREN
216 MONOETHYLGLYCINEXYLIDIDE (MEGX) FORMATION IN PATIENTS WITH LIVER CIRRHOSIS AND SCHISTOSOMAL HEPATIC FIBROSIS
217 MEGX FORMATION AND EXPRESSION OF LIVER CYP3A4 mRNA COMPARED IN PEDIATRIC PATIENTS WITH CHRONIC END STAGE LIVER DISEASE
218 DYNAMIC RENAL FUNCTION TESTS FOR THE MONITORING OF RENAL TRANSPLANT RECIPIENTS
219 DETERMINATION OF MONOETHYLGLYCINEXYLIDIDE (MEGX) BY FPIA IN SERUM SAMPLES WITH HIGH BILIRUBIN
220 DEVELOPMENT OF A SERIES OF MARKERS OF RENAL FUNCTION - USEFUL FOR DOSAGE PREDICTION IN THE IMMUNOSUPPRESSED?
221 EXTENDED 13C-METHACETIN BREATH TEST FOR HEPATIC FUNCTION
222 THE INFLUENCE OF THE ANTITUBERCULOTIC DRUGS ON BIOCHEMICAL PARAMETERS IN PATIENTS WITH PULMONARY TUBERCULOSIS
223 AN EVALUATION OF AN AUTOMATED CARBAMAZEPINE ASSAY ON THE ACS
224 AN EVALUATION OF AN AUTOMATED GENTAMICIN ASSAY ON THE ACS
225 ELECTROSPRAY-MASS SPECTROMETRY - A POWERFUL DETECTION METHOD FOR AUTOMATED QUANTIFICATION OF MACROLIDE IMMUNOSUPPRESSANTS IN BLOOD
226 IMPROVED AND SIMULTANEOUS DETERMINATION OF SSRI ANTIDEPRESSANTS USING GC/ECD OR ION-TRAP GC/MS
227 COMPARISON BETWEEN CEDIA, TDX, EMIT, AND HPLC METHODS FOR CYCLOSPORINE A
228 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH A BASIC MOBILE PHASE IMPROVES CHROMATOGRAPHIC PERFORMANCE OF BASIC DRUGS
229 SOME ASPECTS OF EXTERNAL QUALITY ASSESSMENT IN MEASURING THEOPHYLLINE AND DIGOXIN
230 FEASIBILITY OF QUANTITATION OF SERUM ALFENTANIL USING A QUALITATIVE KIT
231 DETECTION AND QUANTIFICATION OF LICIT AND ILLICIT DRUGS IN SERUM BY ToF-SIMS
232 3,4, METHYLENEDIOXYAMPHETAMINE (MDA) AND 3,4, METHILENEDIOXYMETHAMFETAMINE (MDMA) DETERMINATION AFTER RAPID DERIVATIZATION WITH TRIFLUOROACETIC ACID BY HPLC AND GC/MS
233 COMPARISON OF CLINICAL CHEMISTRY VALUES OF BLOOD SAMPLES OBTAINED FROM RETROBULBAR PLEXUS AND TONGUE VEIN IN RATS
234 ESTABLISHMENT OF A QUALITY ASSURANCE PROGRAM FOR PERHEXILINE IN AUSTRALIAN LABORATORIES
235 EVALUATION OF CONTROL SURVEYS ON TDM 1993-96
236 FULLY AUTOMATED GC/MS DRUG SCREENING IN URINE AND PLASMA SAMPLES